Fetal trimethadione syndrome

Fetal trimethadione syndrome (also known as tridione embryopathy or fetal trimethadione effects) is a rare congenital condition caused by prenatal exposure to trimethadione (Tridione), an anticonvulsant medication previously used to treat absence (petit mal) seizures. This is not an inherited genetic disorder but rather a teratogenic embryopathy, meaning it results from the toxic effects of the drug on the developing fetus during pregnancy. The syndrome affects multiple body systems. Key clinical features include characteristic craniofacial abnormalities such as a broad nasal bridge, V-shaped eyebrows, short upturned nose, and prominent forehead. Affected individuals frequently present with congenital heart defects (particularly septal defects), cleft lip and/or cleft palate, growth retardation (both prenatal and postnatal), microcephaly, and developmental delay or intellectual disability. Urogenital anomalies, limb abnormalities, and ear malformations with associated hearing loss have also been reported. The syndrome carries a significant risk of spontaneous abortion and stillbirth. There is no specific cure for fetal trimethadione syndrome. Management is supportive and multidisciplinary, focusing on the specific malformations present in each individual. This may include surgical correction of cardiac defects or cleft palate, speech therapy, hearing aids, and educational support for developmental delays. Prevention is the most important strategy — trimethadione is now rarely used, and it is strongly contraindicated during pregnancy. Women of childbearing age requiring anticonvulsant therapy are counseled to use alternative medications with lower teratogenic risk.

Common questions about Fetal trimethadione syndrome